LunaRx vs. Ro: GLP-1 Telehealth Compared
Pricing, formulations, and clinical approach — how LunaRx differs from Ro's GLP-1 program.
Disclosure
The GLP Journal is published by LunaRx, so this comparison is written with that conflict disclosed. We aim for accuracy, not advocacy. Compounded GLP-1s are not FDA-approved, and since the 2025 shortage delistings they can only be dispensed in narrow, patient-specific circumstances. This is not medical advice.
LunaRx and Ro both offer GLP-1 telehealth. The difference is in the care model and how each positions the 'coming off' question.
| LunaRx | Ro | |
|---|---|---|
| Model | Physician-led, clinician sets plan | All-in-one telehealth platform |
| Supply | Compounded, via 503A and 503B partner facilities | Compounded and/or brand, varies |
| Differentiator | 'Come off clean' focus | Bundled services, brand |
| Pricing | Tiered; itemize | Bundled monthly; can be opaque |
Should you choose LunaRx or Ro?
- LunaRx — if you want a clinician setting your plan and an explicit taper/exit strategy.
- Ro — if you want a broad telehealth platform with multiple services under one roof.
What should you verify with LunaRx and Ro?
- Is this the FDA-approved product or a compounded one? If compounded, what clinically significant difference has the prescriber documented for you? Since the 2025 shortage delistings that documentation is what the remaining exception turns on.
- Total monthly cost — bundled pricing can hide the real per-item cost.
- What happens to your plan and price if you stop.
Bottom line
Both are legitimate telehealth options with different models. LunaRx leans clinician-led with an explicit coming-off focus; Ro leans bundled platform. We disclose we publish this comparison. Verify pricing and fit — this is information, not a recommendation.
Sources
Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.
- 1.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · 2025
Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.
- 2.Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A
U.S. Food and Drug Administration, guidance for industry · 2018
A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.
- 3.FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. Food and Drug Administration · 2026
April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.
Get the weekly research update
New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.
Unsubscribe anytime. Read our privacy policy.